Table 2.

Comparative characteristics before tocilizumab administration between the well-responding group and rapidly-worsening group.

Characteristic	Well-responding group (n = 7)	Rapidly-worsening group (n = 4)	P -value
Age (years)	61.6 ± 14.7	61.0 ± 13.3	0.7763
Comorbidities	DM (n = 3) HT (n = 2) COPD (n = 1) NTM (n = 1)	DM (n = 1) HT (n = 2) Obesity (n = 1)
Laboratory data
CRP (mg/dL)	9.88 ± 3.88	6.05 ± 2.08	0.0726
Lymphocytes (cells/μL)	834.7 ± 404.6	730.8 ± 196.5	0.5083
Ferritin (ng/mL)	773.3 ± 546.1	1818.7 ± 1046.0	0.0726
Ferritin/CRP	83.67 ± 56.68	373.1 ± 346.8	0.0298

DM, diabetes mellitus; HT, hypertension; COPD, chronic obstructive pulmonary diseases; NTM, non-tuberculous mycobacteriosis; CRP, C-reactive protein.